Sartorius, founded in 1870 by Wilhem Sartorius von Waltershausen, is a leading international laboratory and process technology provider. In 1997, the company went public on the Frankfurt Stock Exchange and became part of the MDAX index, representing Germany’s mid-sized market cap companies.
Today, Sartorius has over 8,000 employees and business partners in more than 110 countries around the world. The company’s market cap exceeds $26 billion as of November 2022. Traders who are interested in Sartorius can take advantage of its growth potential by investing in its stock. The company’s long history of success, innovative technologies and strong partnerships make it an attractive investment opportunity for traders. With Sartorius, traders can benefit from the potential of a world-renowned company with strong fundamentals and a long history of growth.
Sartorius's share price has been on a steady rise since 2016, with the stock hitting its highest point of €757 in September 2021. This was mostly due to strong demand for their bioprocessing solutions and laboratory products as well as increasing sales. However, the stock took a dive in mid-March 2022 after reports of delays in new product launches as well as a slowdown in revenue growth. Since then, the stock has yet to recover.
Investors should be aware that any negative news concerning Sartorius could lead to further price declines. Over the long term, however, prospects for the company remain strong and it is likely that the share price will recover in time. As such, Sartorius could still be a good option for investors looking for attractive returns over the next few years.
The market is filled with the competition when it comes to Sartorius. Companies like Thermo Fisher, Agilent, and Danaher are all in the race to provide the best products. Despite their differences, these companies have one thing in common: they are all vying for the top spot in terms of stock prices. Sartorius boasts a strong stock price with its shares trading at over $300, which shows that Sartorius has a lot of potential for growth and is an attractive option for investors.
At the same time, it's important to consider the strengths and weaknesses of each company. Sartorius has a reputation for high-quality products and reliable customer service, giving it an edge over its competitors. On the other hand, Agilent and Danaher have a wider reach and are able to offer more comprehensive services. Thermo Fisher is well known for its advanced technology and research capability which could give them an advantage in the medical devices market.
|[[ data.swapLong ]] points
|[[ data.swapShort ]] points
|[[ data.stats.minSpread ]]
|[[ data.stats.avgSpread ]]
|Min contract size
|[[ data.minVolume ]]
|Min step size
|[[ data.stepVolume ]]
|Commission and Swap
|Commission and Swap
* The spreads provided are a reflection of the time-weighted average. Though Skilling attempts to provide competitive spreads during all trading hours, clients should note that these may vary and are susceptible to underlying market conditions. The above is provided for indicative purposes only. Clients are advised to check important news announcements on our Economic Calendar, which may result in the widening of spreads, amongst other instances.
The above spreads are applicable under normal trading conditions. Skilling has the right to amend the above spreads according to market conditions as per the 'Terms and Conditions'.
What are the key factors that could affect Sartorius AG's stock price?
Several key factors could impact Sartorius AG's stock price. One significant factor is the overall performance and outlook of the pharmaceutical and biotech industries, as the company operates in these sectors. Any advancements or setbacks in drug development, regulatory changes, or shifts in healthcare trends could influence investor sentiment and subsequently affect the stock price.
Economic conditions and market trends, such as inflation, interest rates, and global demand for lab equipment, could also play a role. Additionally, company-specific factors such as earnings reports, product launches, mergers and acquisitions, and changes in leadership could impact the stock price. It's crucial for traders to closely monitor these factors to make informed decisions.
Who owns the most Sartorius AG shares?
As of September 2023, the largest shareholders of Sartorius AG (SATG_p.DE) include institutional owners such as Vanguard Total International Stock Index Fund Investor Shares (VGTSX), Vanguard Developed Markets Index Fund Admiral Shares (VTMGX), AllianzGI Global Sustainability Fund Class A (ASUAX), Vanguard UK100 All-World ex-US Index Fund ETF Shares (VEU), Vanguard European Stock Index Fund Investor Shares (VEURX), Schwab International Equity ETF (SCHF), AllianzGI NFJ International Value Fund A (AFJAX), Vanguard Total World Stock Index Fund ETF Shares (VT), Schwab Fundamental International Small Company Index ETF (FNDC), and Invesco UK100 RAFI Developed Markets ex-U.S. Small-Mid ETF (PDN).
These institutions collectively hold a total of 75,146 shares in Sartorius AG.
Does Sartorius AG pay dividend?
Yes, Sartorius AG does pay dividends. According to the historical dividend data, Sartorius AG has paid dividends on the following dates:
• Ex-Dividend Date: Mar 30, 2023; Dividend: €1.43
• Ex-Dividend Date: Mar 28, 2022; Dividend: €1.25
• Ex-Dividend Date: Mar 29, 2021; Dividend: €0.7
• Ex-Dividend Date: Jun 29, 2020; Dividend: €0.35
• Ex-Dividend Date: Mar 29, 2019; Dividend: €0.61
• Ex-Dividend Date: Apr 06, 2018; Dividend: €0.5
Why Trade [[data.name]]
Make the most of price fluctuations - no matter what direction the price swings and without capital restrictions that come with buying the underlying asset.